Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood

Hagemann A, Klimpel D, Schmitter E, Bien C, Dufaux B, May T, Brandt C (2022)
Therapeutic Drug Monitoring.

Zeitschriftenaufsatz | E-Veröff. vor dem Druck | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Hagemann, Anne; Klimpel, Dennis; Schmitter, Elisabeth; Bien, ChristianUniBi; Dufaux, Bertin; May, TheodorUniBi; Brandt, ChristianUniBi
Abstract / Bemerkung
BACKGROUND: Estimation of serum concentrations of antiseizure medications (ASMs) based on dried capillary blood is an alternative method for therapeutic drug monitoring of epilepsy. The aim of this study was to validate the conversion factors for lacosamide (LCM), lamotrigine (LTG), and levetiracetam (LEV), which were determined in an independent patient sample in a previous study, and identify the most accurate conversion method (simple ratio, regression).; METHODS: Venous and capillary blood samples were collected from adult inpatients with epilepsy treated with LCM (n=25), LTG (n=27), and/or LEV (n=29) before the morning dose (T1) and approximately 2 h after (T2). Capillary blood was collected using volumetric absorptive microsampling, and the ASM concentrations were measured using a validated liquid chromatography-mass spectrometry method for dried blood samples. Serum concentrations were estimated using conversion factors and compared with those measured using routine laboratory methods.; RESULTS: For all three ASMs, the simple ratio approach performed better than the regression approach. Intraclass correlation coefficients revealed a high agreement between the estimated and measured serum concentrations (LCM T1: 0.93, T2: 0.90; LTG T1: 0.91, T2: 0.91; LEV T1: 0.97, T2: 0.94). The criteria of the European Medicines Agency for cross-validation were fulfilled for LCM (T1: 72%; T2: 75%) and LEV (T1: 86%; T2: 75%), whereas for LTG, this was only true for capillary blood concentrations ≤11 g/mL [42.9 mol/L; T1: 72% (vs. 63% for total range), T2: 67% (vs. 62%)].; CONCLUSIONS: Estimating serum concentrations using capillary blood concentrations is feasible and accurate for LCM and LEV over a wide concentration range, as found in clinical practice. The applicability of this method for LTG is limited by its greater variability at higher concentrations; however, acceptable results were achieved for the large proportion of patients with low and medium LTG concentrations. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Erscheinungsjahr
2022
Zeitschriftentitel
Therapeutic Drug Monitoring
eISSN
1536-3694
Page URI
https://pub.uni-bielefeld.de/record/2966838

Zitieren

Hagemann A, Klimpel D, Schmitter E, et al. Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood. Therapeutic Drug Monitoring. 2022.
Hagemann, A., Klimpel, D., Schmitter, E., Bien, C., Dufaux, B., May, T., & Brandt, C. (2022). Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood. Therapeutic Drug Monitoring. https://doi.org/10.1097/FTD.0000000000001056
Hagemann, Anne, Klimpel, Dennis, Schmitter, Elisabeth, Bien, Christian, Dufaux, Bertin, May, Theodor, and Brandt, Christian. 2022. “Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood”. Therapeutic Drug Monitoring.
Hagemann, A., Klimpel, D., Schmitter, E., Bien, C., Dufaux, B., May, T., and Brandt, C. (2022). Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood. Therapeutic Drug Monitoring.
Hagemann, A., et al., 2022. Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood. Therapeutic Drug Monitoring.
A. Hagemann, et al., “Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood”, Therapeutic Drug Monitoring, 2022.
Hagemann, A., Klimpel, D., Schmitter, E., Bien, C., Dufaux, B., May, T., Brandt, C.: Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood. Therapeutic Drug Monitoring. (2022).
Hagemann, Anne, Klimpel, Dennis, Schmitter, Elisabeth, Bien, Christian, Dufaux, Bertin, May, Theodor, and Brandt, Christian. “Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood”. Therapeutic Drug Monitoring (2022).

Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 36302342
PubMed | Europe PMC

Suchen in

Google Scholar